Cytori Therapeutics (CYTX) Misses Q2 EPS by 14c

Cytori Therapeutics (NASDAQ: CYTX) reported Q2 EPS of ($0.59), $0.14 worse than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
• ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy